Table of Contents Author Guidelines Submit a Manuscript
Journal of Thyroid Research
Volume 2011, Article ID 306487, 4 pages
http://dx.doi.org/10.4061/2011/306487
Clinical Study

Occurrence of Type 1 Diabetes in Graves' Disease Patients Who Are Positive for Antiglutamic Acid Decarboxylase Antibodies: An 8-Year Followup Study

1Division of Endocrinology & Metabolism, Department of Internal Medicine, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501, Japan
2Department of Internal Medicine, Tokyo Denryoku Hospital, 9-2 Shinanomachi, Shinjuku-ku, Tokyo 160-0016, Japan
3Ito Hospital, 4-3-6 Jingumae, Shibuya-ku, Tokyo 150-8308, Japan

Received 31 August 2010; Revised 27 November 2010; Accepted 7 December 2010

Academic Editor: Gary L. Francis

Copyright © 2011 Matsuo Taniyama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Glutamic acid decarboxylase antibodies (GADAs) are one of the markers of islet cell autoimmunity and are sometimes present before the onset of type 1 diabetes (T1D). GADA can be present in Graves' patients without diabetes; however, the outcome of GADA-positive Graves' patients is not fully understood, and the predictive value of GADA for the development of T1D in Graves' patients remains to be clarified. We investigated the prevalence of GADA in 158 patients with Graves' disease and detected GADA in 10 patients. They were followed up to discover whether or not T1D developed. In the course of eight years, 2 patients with high titers of GADA developed T1D, both had long-standing antithyroid drug-resistant Graves' disease. Thus, Graves' disease with high GADA titer seems to be at high risk for T1D.